Sven de Vos
- Pathology and Forensic Medicine top 0.1%
- Oncology top 0.5%
- Genetics top 0.2%
- Molecular Biology top 5%
- Immunology top 2%
- Co-authors
- H. Phillip KoefflerJohn P. LeonardDieter HoelzerWolf‐K. HofmannAndres Forero‐TorresJeff P. SharmanStephen M. AnsellBrad S. Kahl
- Topics
- Lymphoma Diagnosis and Treatment (114 papers)Chronic Lymphocytic Leukemia Research (87 papers)CAR-T cell therapy research (58 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Sven de Vos
186 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 114
- Pathology and Forensic Medicine 3.9k
- Oncology 3.6k
- Genetics 2.6k
- Molecular Biology 2.1k
- Immunology 1.3k
Countries citing papers authored by Sven de Vos
This map shows the geographic impact of Sven de Vos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven de Vos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven de Vos more than expected).
Fields of papers citing papers by Sven de Vos
This network shows the impact of papers produced by Sven de Vos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven de Vos. The network helps show where Sven de Vos may publish in the future.
Co-authorship network of co-authors of Sven de Vos
This figure shows the co-authorship network connecting the top 25 collaborators of Sven de Vos. A scholar is included among the top collaborators of Sven de Vos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven de Vos. Sven de Vos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 3 | |
| 3 | 0 | |
| 4 | 7 | |
| 5 | 0 | |
| 6 | 1 | |
| 7 | 5 | |
| 8 | 18 | |
| 9 | 13 | |
| 10 | 2 | |
| 11 | Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trialbreakdown → | 186 |
| 12 | 8 | |
| 13 | 20 | |
| 14 | 54 | |
| 15 | Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphomabreakdown → | 1014 |
| 16 | 4 | |
| 17 | 150 | |
| 18 | 29 | |
| 19 | 35 | |
| 20 | 96 |
About Sven de Vos
Sven de Vos is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology, having authored 192 papers that have together received 7.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (114 papers), Chronic Lymphocytic Leukemia Research (87 papers) and CAR-T cell therapy research (58 papers). The work is most often cited by research in Genetics (2.6k citations), Pathology and Forensic Medicine (3.9k citations) and Oncology (3.6k citations). Sven de Vos has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include H. Phillip Koeffler, John P. Leonard, Dieter Hoelzer, Wolf‐K. Hofmann, Andres Forero‐Torres, Jeff P. Sharman, Stephen M. Ansell, Brad S. Kahl, Robert Chen and Kerry J. Savage. Their work appears in journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.